Hypoalbuminemia predicts inferior outcome in patients with AIDS-related lymphoma

Abstract

Background The prognostic value of serum albumin in acquired immunodeficiency syndrome (AIDS)-related lymphoma (ARL) remains covered. Methods We retrospectively analyzed de novo ARL patients from 2013 to 2019 across three centers. Factors correlated with progression-free survival (PFS) and overall survival (OS) were evaluated in Kaplan–Meier, univariate and multivariate Cox proportional hazard models. Results A total of 86 ARL patients were enrolled with a median follow-up of 34 months. In the cohort, the OS and 2-year PFS rates were 37.5% and 35.4%, respectively. In multivariate models, older age (PFS, hazard ratios [HR] = 1.035, p = 0.037; OS, HR = 1.034, p = 0.041) and hypoalbuminemia (OS, HR = 0.910, p = 0.038) predicted inferior survival. ARL patients with hypoalbuminemia showed worse OS and 2-year PFS (p = 0.028 and p = 0.01, respectively), which was associated with poor Eastern Cooperative Oncology Group performance status (ECOG PS) and higher International Prognosis Index (IPI) score. Conclusion In conclusion, serum albumin at diagnosis is an independent prognostic factor for overall survival in AIDS-related lymphoma.

Diffuse Large B-Cell Lymphoma in the Public-Sector of Johannesburg, South Africa, in the Era of Widescale Antiretroviral Therapy Use

“…The independent negative impact of hypoalbuminemia has been demonstrated previously in a study from China, where patient age also played a significant role in AIDS-related lymphoma outcomes. 35 Survival times were not influenced by patient age ($60 years), Ki-67 levels ($80%), extranodal disease (apart from BMi), COO, or gender in this cohort. Survival rates seemed poorer in the MYC+ cases, but this finding was not statistically significant, possibly because of the limited number of MYC+ cases with survival data.…”